Opinion
Video
Highlights from ASH 2023 in Transplant-Eligible NDMM
Author(s):
Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies.
EP: 1.The Evolving Landscape of Newly Diagnosed Multiple Myeloma
EP: 2.Highlights from ASH 2023 in Transplant-Eligible NDMM
EP: 3.Advances in the Treatment of High-Risk MM
EP: 4.Role of Transplant and MRD in Newly Diagnosed MM
EP: 5.The Evolving Treatment Paradigm for Transplant Ineligible MM
EP: 6.Treatment of Multiple Myeloma at Early Relapse
EP: 7.Potential Role for CAR T-Cell Therapy in MM at Early Relapse
EP: 8.Updates on BCMA-Targeting Bispecifics in MM
EP: 9.Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma
EP: 10.Step-Up Dosing Practices for Bispecifics in Multiple Myeloma
EP: 11.Adverse Effects Related to Bispecifics in Multiple Myeloma
EP: 12.GPRC5D-Targeting Bispecifics in Multiple Myeloma
EP: 13.CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape
EP: 14.Treatment Considerations and Sequencing in Multiple Myeloma
This is a video synopsis/summary of a Peer Exchange featuring Krina K. Patel, MD, MSc; Amrita Krishnan, MD; Caitlin Costello, MD; Saad Z. Usmani, MD, MBA, FACP; and Rafat Abonour, MD.
The experts discuss recent study results presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition regarding adding daratumumab to standard triplet induction, transplant consolidation, and maintenance therapy for newly diagnosed, transplant-eligible multiple myeloma patients.
The GRIFFIN trial showed improved stringent complete response rates with quadruplet induction including daratumumab vs triplet induction. The PERSEUS trial confirmed these findings in a larger phase 3 study, demonstrating improved progression-free survival at 4 years (84% vs 67%) and higher complete response and minimal residual disease negativity rates with quadruplet induction and maintenance including daratumumab. However, it is unclear if the benefit is from induction alone or requires continuous daratumumab therapy.
In real-world practice, consolidation post transplant and doublet maintenance is not universally used. The question remains if quadruplet induction alone is sufficient or if daratumumab should be incorporated into maintenance as well, especially for high-risk patients who may derive more benefit. Ongoing studies like the SWOG S1803 trial will provide more evidence regarding optimal maintenance strategies.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
